Expansion funding Cirdan has secured significant equity and venture debt funding totaling over £7 million in 2026, alongside a new £4 million debt facility. This financing signals capacity for international expansion, product development, and scaling sales efforts into new markets.

Global footprint ULTRA LIS is already installed in more than 80 laboratories across 6 continents, with recent go-lives including Nottingham University Hospitals NHS Trust. This demonstrates a proven model for international integration and potential for upsell within existing customers and new regions.

Healthcare focus The company specializes in pathology and clinical laboratory software, offering an advanced Laboratory Information System (LIS). This positions Cirdan to cross-sell modules, analytical tools, and imaging solutions to hospitals, pathology labs, and national health networks seeking workflow efficiencies.

Strategic partnerships Recent collaborations and student intake expansions indicate a growth mindset and potential for co-sell opportunities, professional services expansion, and joint development with academic and health system partners to accelerate adoption of ULTRA.

Productivity leverage The emphasis on imaging, MATLAB-based workflows, and cloud-enabled infrastructure suggests opportunities to position ULTRA as a scalable, cloud-connected LIS via Microsoft Azure and Google Cloud, appealing to labs pursuing digital transformation and data-driven diagnostics.